CXCL12 and Miyoshi myopathy: Additionally, ibrutinib, a BTK inhibitor, could reduce the surface membrane levels of CXCR4 in chronic lymphocytic leukemia and downregulate the migration of MM cells toward SDF-1 and homing to the BM microenvironment [63,64].